[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1- FINLAY-FR-2 (Experimental): Low dose conjugated RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. Booster dose 45-60 days after 2nd Doses: 10 subjects with FINLAY-FR-2 (Experimental): low dose of conjugated RBD+adjuvant; 0;5 mL; intramuscular (IM) and 10 subjects with FINLAY-FR-1A 50 ug dRBD/alumina; 0;5 mL;intramuscular (IM)Group 2- FINLAY-FR-2 (Experimental): High dose conjugated RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. Booster dose 45-60 days after 2nd Doses: 10 subjects with FINLAY-FR-2 (Experimental): high dose of conjugated RBD+adjuvant; 0;5 mL; intramuscular (IM) and 10 subjects with FINLAY-FR-1A 50 ug dRBD/alumina; 0;5 mL;intramuscular (IM);Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "Low dose;0.5 mL;2 (0-28 days);IM", "treatment_id": 515, "treatment_name": "Finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "High dose;0.5 mL;2 (0-28 days);IM", "treatment_id": 515, "treatment_name": "Finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1- FINLAY-FR-2 (Experimental): Low dose conjugated RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. Booster dose 45-60 days after 2nd Doses: FINLAY-FR-2 (Experimental): low dose of conjugated RBD+adjuvant; 0;5 mL; intramuscular (IM) \u00f3 FINLAY-FR-1A 50 ug dRBD/alumina; 0;5 mL;intramuscular (IM)Group 2- FINLAY-FR-2 (Experimental): High dose conjugated RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. Booster dose 45-60 days after 2nd Doses: FINLAY-FR-2 (Experimental): high dose of conjugated RBD+adjuvant; 0;5 mL; intramuscular (IM) \u00f3 FINLAY-FR-1A 50 ug dRBD/alumina; 0;5 mL;intramuscular (IM);Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1- FINLAY-FR-2 (Experimental): Low dose conjugated RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. Group 2- FINLAY-FR-2 (Experimental): High dose conjugated RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose.;Immunogenicity; Vaccine", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]